Compare MIRM & SKYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | SKYH |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 324.6M |
| IPO Year | 2019 | N/A |
| Metric | MIRM | SKYH |
|---|---|---|
| Price | $65.05 | $9.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $87.55 | $13.83 |
| AVG Volume (30 Days) | ★ 560.0K | 140.7K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $471,794,000.00 | $24,125,000.00 |
| Revenue This Year | $53.78 | $95.10 |
| Revenue Next Year | $19.91 | $71.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 53.66 | ★ 95.23 |
| 52 Week Low | $36.88 | $8.22 |
| 52 Week High | $78.55 | $14.20 |
| Indicator | MIRM | SKYH |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 53.83 |
| Support Level | $63.66 | $9.39 |
| Resistance Level | $66.77 | $9.84 |
| Average True Range (ATR) | 2.99 | 0.37 |
| MACD | -0.66 | 0.10 |
| Stochastic Oscillator | 13.68 | 79.46 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.